Revian to Present Poster at 2024 Investigative Dermatology Meeting

Revian Inc., a pioneering company in aesthetic medical technology, will showcase significant findings at the 2024 Society for Investigative Dermatology Annual Meeting, set to take place in Dallas from May 15-18, 2024. The company's key presentation will be delivered by Dr. Jacob Kocher, who will reveal data demonstrating that Revian's patented LED light therapy can reduce Dihydrotestosterone (DHT) production by 74%. This reduction is a substantial improvement over the industry-standard treatment, finasteride, which only achieves a 38% reduction in DHT production within 24 hours post-treatment.

DHT is known to play a critical role in androgenic alopecia, commonly referred to as pattern hair loss. Revian's breakthrough could offer a more effective and less invasive solution compared to systemic drugs, which often come with serious side effects. John Oakley, Chief Executive Officer of Revian, emphasized the importance of this development, noting that the company's technology offers a healthier alternative for those seeking to prevent hair loss.

Dr. Kocher's presentation is titled "Inhibition of dihydrotestosterone (DHT) formation via dual wavelength orange-red light production of nitric oxide." This presentation falls under the Translational Studies and Early Preclinical to Clinical category and will be held on May 17th from 4:00-6:00 PM at the Trinity Exhibit Hall in the Hilton Anatole, Dallas.

Revian's innovation lies in its use of a patented combination of 620 nm and 660 nm wavelengths. These specific wavelengths are proven to block DHT production more effectively than finasteride. The technology is encapsulated in the REVIAN RED System, an FDA-cleared, lightweight wireless cap controlled via a mobile app. This system offers a convenient, non-invasive treatment option for both men and women experiencing hair loss.

The REVIAN RED System leverages dual wavelength LED technology, which provides comprehensive scalp coverage and superior skin penetration. The device stimulates the production and release of nitric oxide, which increases local blood flow, reduces inflammation, and inhibits DHT production, creating an optimal environment for hair growth. The system is indicated for treating androgenetic alopecia, promoting hair growth in males with Norwood-Hamilton classifications of IIa-V patterns of hair loss, and in females with Ludwig-Savin Scale I-1 to II-4, II1, II2, or frontal patterns of hair loss. It is suitable for individuals with Fitzpatrick Skin Types I-IV.

Revian, a subsidiary of KNOW Bio, LLC, focuses on using precise wavelengths of light to rejuvenate hair and skin. The company's products enable users to harness the regenerative potential of light within the comfort of their homes. Committed to scientific rigor, Revian collaborates closely with healthcare providers to deliver meaningful, data-backed results.

This upcoming presentation at the Society for Investigative Dermatology Annual Meeting marks a milestone in hair loss research, offering new hope for those suffering from androgenic alopecia. Revian's LED light therapy could revolutionize the treatment landscape, providing an effective, side-effect-free alternative to existing therapies.